Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||RET fusion|
|Indication/Tumor Type||thyroid gland cancer|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RET fusion||thyroid gland cancer||sensitive||Selpercatinib||FDA approved - On Companion Diagnostic||Actionable||In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate of 79% (15/19), including one complete and 14 partial responses, with a median response duration of 18.4 months, and median progression-free survival of 20.1 months in adult and pediatric patients 12 years and older with RET fusion-positive thyroid cancer who were previously treated (PMID: 32846061; NCT03157128).||detail... detail... 32846061|
|PubMed Id||Reference Title||Details|
|Retevmo (selpercatinib) FDA Drug Label||Full reference...|
|(32846061)||Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.||Full reference...|